Use of biodegradable microspheres that release an anticancer...

Details Use of biodegradable microspheres that release an anticancer... Use of biodegradable microspheres that release an anticancer...

2006-05-09

2006-05-09

Azpuru, Carlos A. (Department: 1615)

Plastic and nonmetallic article shaping or treating: processes

Encapsulating normally liquid material

Liquid encapsulation utilizing an emulsion or dispersion to...

C264S004330, C264S004600, C427S213300

Reexamination Certificate

active

07041241

ABSTRACT:
The invention relates to the use of biodegradable microspheres that release a radiosensitizing anticancer agent for producing a medicament to be used simultaneously with, separately from or spread over time with a radiotherapy, for treating glioblastoma. The use of said biodegradable microspheres according to the invention results in a patient survival time of at least 90 weeks, a therapeutically effective concentration being maintained in the parenchymatous area throughout this time. The microspheres used preferably contain 5-fluorouracile of the tumor, by intratissular injection. The radiotherapy targeting the tumorous mass is dosed at 60 Gy over approximately 6 weeks. The invention also relates to a method for producing the biodegradable microspheres by emulsion-extraction, and to a suspension containing the biodegradable microspheres obtained using this method.

REFERENCES:
patent: 5534269 (1996-07-01), Igari et al.
patent: 5846565 (1998-12-01), Brem et al.
patent: 2 693 905 (1994-01-01), None
Liggins et al., Paclitaxel loaded Poly(L-lacric acid) microspheres for the prevention of intraperitoneal carcinomatosis after a suprgical repair and tumor cell spill, Biomaterials, vol. 21, Issue 19, Oct. 2000, pp. 1959-1969.
N. Aoki, “Reversible Leukoencephalopathy Caused by 5-Fluorouracil Derivatives, Presenting as Akinetic Mutism,”Surg. Neurol.1986 25:279-282 Elsevier Science Publishing Co., Inc.
M.A. Bagshaw, “Possible Role of Potentiators in Radiation Therapy,”Symposium on Interrelationships of Recent Advances in Radiobiology and Radiation TherapyMay 1961, 85(5):822-833.
Benoit, J.P. et al. “Radiosensitization of Glioblastoma After Intracranial Implantation of Biodegradable 5-Fu-Loaded Microspheres: Phase I Clinical Trial,”Proceedings 1997 of the 24thInternational Symposium on Controlled Release of Bioactive Materials(1997), pp. 995-996, Controlled Release Society, Inc.
M. Boisdron-Celle et al., “Preparation and Characterization of 5-Fluorouracil-loaded Microparticles as Biodegradable Anticancer Drug Carriers,”J. Pharm. Pharmacol.1995, 47:108-114.
R.S. Bourke et al., “Kinetics of Entry and Distribution of 5-Fluorouracil in Cerebrospinal Fluid and Brain following Intravenous Injection in a Primate,”Cancer ResearchJul. 1973, 33:1735-1746.
H. Brem et al., “Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas,”J. Neurosurg.Mar. 1991 74:441-446.
H. Brem, “Polymers to treat brain tumours,”BiomaterialsNov. 1990, 11:699-701, Butterworth-Heinemann Ltd.
H. Brem, et al., “Polymers as Controlled Drug Delivery Devices for the Treatment of Malignant Brain Tumors,”Eur. J. Pharm. Biopharm.1993 39(1):2-7, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, Fed. Rep. of Germany.
H. Brem et al., “Placebo-controlled trial of safety and efficacy of intraoperative controled delivery by biodegradable polymers of chemotherapy for recurrent gliomas,”The Lancet,Apr. 1995, 345:1008-1012.
D.F. Emerich et al., “Injectable Chemotherapeutic Microspheres and Glioma II: Enhanced Survival Following Implantation into Deep Inoperable Tumors,”Pharmaceutical Research2000 17(7)776-781, Plenum Publishing Corporation.
E.J. Frazza et al., “A New Absorbable Suture,”J. Biomed. Mater. Res. Symposium1971 1:43-58, John Wiley & Sons, Inc.
M.A. Gerosa et al., “Improved treatment of a brain-tumor model,”J. NeurosurgMar. 1983 58:368-373.
T.E. Goffman et al., “Long-Term Follow-Up on National Cancer Institute Phase I/II Study of Glioblastoma Multiforme Treated with Iododeoxyuridine and Hyperfractionated Irradiation,”Journal of Clinical OncologyFeb. 1992, 10(2):264-268.
R. Jalil et al., “Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microscapsules: problems associated with preparative techniques and release properties,”J. Microencapsulation1990, 7(3):297-325, Taylor & Francis Ltd.
P. Kornblith et al., “Chemotherapy for malignant gliomas,”J. Neurosurg., 68:1-17, 1988.
D.G. Kotsilimbas et al., “Evaluation of parenteral 5-FU on experimental brain tumors,”Neurology1966 16:916-918.
J.H. Kou et al., “Bioerosion and biocompatibility of poly(d,I-lactic-co-glycolic acid) implants in brain,”Journal of Controlled Release1997, 43:123-130 Elsevier Science Ireland Ltd.
W.R. Shapiro, “Studies on the Chemotherapy of Experimental Brain Tumors: Evaluation of 1-(2-Chloro-ethyl)-3-Cyclohexyl-1-Nitrosourea, Vincristine, and 5-Fluorouracil,”Journal of the National Cancer Institute1971 46(2):359-368.
W.R. Shapiro et al., “A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma,”J. Neurosurg.1992 76:772-781.
A.H. Soloway et al., “Chemotherapy of Brain Tumors. I. Transplanted Murine Ependymoblastomas,”Cancer Chemotherapy Reports, Mar. 1964 36:1-4.
Y.. Oda et al., “Trial of Anticancer Pellet in Malignant Brain Tumours; 5 FU and Urokinase Embedded in Silastic,”Acta Neurochirurgica, Suppl.1979 28:489-490, Springer-Verlag.
R.J. Tamargo et al., “Drug Delivery to the Central Nervous System: A Review,”Neurosurgery Quarterly1992 2(4):259-279, Raven Press, Ltd., New York.
A.I. Torres et al., “Formulation of BCNU-loaded microspheres: influence of drug stability and solubility on the design of the microencapsulation procedure,”J. Microencapsulation1996 13(1):41-51, Taylor & Francis Ltd.
T. Vietti et al., “Combined Effect of X Radiation and 5-Fluorouracil on Survival of Transplanted Leukemic Cells,”Journal of the National Cancer Institute, Oct. 1971 47(4):865-870.
G.E. Visscher et al., “Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules,”Journal of Biomedical Materials Research1985, 19:349-365, John Wiley & Sons, Ltd.
J.A. Koutcher et al., “Radiation Enhancement By Biochemical Modulation and 5-Fluorouracil,”Int. J. Radiation Oncology Biol. Phys.,1997 39(5):1145-1152, Elsevier Science Inc.
Robert Langer, “Polymer imlpants for drug delivery in the brain,”Journal of Controlled Release1991, 16:53-60, Elsevier Science Publishers B.V.
V.A. Levin et al., “5-Fluorouracil and 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) Followed by Hydroxyurea, Misonidazole, and Irradiation for Brain Stem Gliomas: A Pilot Study of the Brain Tumor Research Center and the Childrens Cancer Group,”Neurosurgery14(6):679-381, Congress of Neurological Surgeons.
P. Menei et al., “Biodegradatioon and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres,”Biomaterials1993 14(6):470-478, Butterworth-Heinemann Ltd.
P. Menei et al., “Fate and biocompatibility of three types of microspheres implanted into the brain,”Journal of Biomedical Materials Research1994 23:1079-1085, John Wiley & Sons, Inc.
D.H. Moore et al., “Case Report: 5-Fluorouracil Neurotoxicity,”Genecologic Oncology1990 36:152-154, Academic Press, Inc.
T. Painbeni et al., “Internal morphology of poly(D,L-lactide-co-glycolide) BCNU-loaded microspheres. Influence on drug stability,”European Journal of Pharmaceutics and Biopharmaceutics1998, 45:31-39, Elsevier Science B.V.
R.D. Penn et al., “Chronic Intratumoral Chemotherapy of a Rat Tumor with Cisplatin and Fluorouracil,”Appl. Neurophysiol.1983 46:240-244, S. Karger A.G. Basel.

Affiliated with

Also associated with

Rating

Use of biodegradable microspheres that release an anticancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of biodegradable microspheres that release an anticancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of biodegradable microspheres that release an anticancer... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3553436